Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.70 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.53 |
| ▸ | F2 | P00734 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PLG | P00747 | 1/20 | 0.51 |
| ▸ | PROC | P04070 | 1/20 | 0.51 |
| ▸ | KLK1 | P06870 | 1/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6804794 | 0.92 | F10 (0.59) | F10PRSS1MAPTHIF1AEPAS1 | |
| SCHEMBL6296950 | 0.90 | F10 (0.85) | F10PRSS1F2PLGPROC | |
| SCHEMBL6801213 | 0.84 | SMN1; SMN2 (0.54) | F10PRSS1MAPTHIF1AEPAS1 | |
| SCHEMBL6808035 | 0.82 | GAA (0.56) | F10PRSS1MAPTHIF1AEPAS1 | |
| SCHEMBL7478524 | 0.82 | F10 (1.00) | F10PRSS1PLGPROCKLK1 | |
| SCHEMBL6303558 | 0.81 | F10 (0.84) | F10PRSS1F2PLGPROC | |
| SCHEMBL6807833 | 0.81 | F10 (0.73) | F10PRSS1F2PLGPROC | |
| SCHEMBL6303168 | 0.80 | F10 (0.77) | F10PRSS1F2PLGPROC | |
| SCHEMBL6808404 | 0.78 | HAVCR2 (0.60) | MAPT | |
| SCHEMBL6303962 | 0.78 | F10 (0.60) | F10PRSS1F2PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | claimed |
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | RCOR3, F2, NCOR2 | F10 64/4885PRSS1 1089/4885MAPT 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.